Annexatm-R: A phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor xa (fXa) inhibitors

Category Primary study
JournalJournal of the American College of Cardiology
Year 2015
This article has no abstract
Epistemonikos ID: c49dd16738424099204b03fd47428bb305070b30
First added on: Feb 07, 2025